Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit. Issue 8 (17th August 2018)

• Record Type: Journal Article
• Authors: Nanayakkara, Natalie; Ranasinha, Sanjeeva; Gadowski, Adelle M; Davis, Wendy A; Flack, Jeffrey Ronald; Wischer, Natalie; Andrikopoulos, Sof; Zoungas, Sophia
• Is Part Of: BMJ open. Volume 8:Issue 8(2018)
• Publication Date: 2018-08-17
• Subjects: general diabetes -- epidemiology -- general medicine (see internal medicine); Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-020677
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: To compare the glycaemic control and cardiovascular risk factor profiles of younger and older patients with type 2 diabetes. Cross-sectional analysis of data from the 2015 Australian National Diabetes Audit was undertaken. Methods: Data were obtained from adults with type 2 diabetes presenting to Australian secondary/tertiary diabetes centres. Logistic regression examined associations with glycated haemoglobin A1c (HbA1c) >7% (53 mmol/mol) and cardiovascular risk factors. Results: Data from 3492 patients were analysed. Mean (±SD) age was 62.9±12.5 years, mean diabetes duration 13.5±9.4 years and mean HbA1c 8.2%±1.8%. Mean HbA1c was 8.6%±2.1% and 8.0%±1.6% for the younger (<60 years) and older subgroups (≥60 years), respectively (p<0.001). The adjusted OR (aOR) of HbA1c above >7.0% was 1.5 times higher (95% CI 1.22 to 1.84) for younger patients compared with older patients after adjustment for gender, smoking, diabetes duration, renal function and body mass index. Younger patients were also more likely to have dyslipidaemia (aOR 2.02, 95% CI 1.53 to 2.68; p<0.001), be obese (aOR 1.25, 95% CI 1.05 to 1.49; p<0.001) and be current smokers (aOR 2.13 95% CI 1.64 to 2.77; p<0.001) than older patients. Conclusions: Younger age was associated with poorer glycaemic control and adverse cardiovascular risk factor profiles. It is imperative to optimise and monitor treatment in order to improve long-term outcomes.